MAP3K7CL

Summary

MAP3K7CL (MAP3K7 C-terminal like, HGNC:16457) is a protein-coding gene on chromosome 21q21.3, encoding MAP3K7 C-terminal-like protein (P57077).

Located in cytosol and nucleus.

Source: NCBI Gene 56911 — RefSeq curated summary.

At a glance

• GWAS associations: 35
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_001286620

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16457
Approved symbol	MAP3K7CL
Name	MAP3K7 C-terminal like
Location	21q21.3
Locus type	gene with protein product
Status	Approved
Aliases	TAKL, TAK1L, TAKL-1, TAKL-2, TAKL-4
Ensembl gene	ENSG00000156265
Ensembl biotype	protein_coding
OMIM	611110
Entrez	56911

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 26 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000339024, ENST00000341618, ENST00000399925, ENST00000399926, ENST00000399928, ENST00000399934, ENST00000399935, ENST00000399947, ENST00000419845, ENST00000451489, ENST00000460883, ENST00000470800, ENST00000492930, ENST00000496779, ENST00000545939, ENST00000710354, ENST00000899526, ENST00000899527, ENST00000899528, ENST00000899529, ENST00000899530, ENST00000899531, ENST00000899532, ENST00000899533, ENST00000899534, ENST00000899535, ENST00000946614, ENST00000946615, ENST00000946616, ENST00000946617, ENST00000946618

RefSeq mRNA: 16 — MANE Select: NM_001286620 NM_001286617, NM_001286618, NM_001286619, NM_001286620, NM_001286622, NM_001286623, NM_001286624, NM_001286634, NM_001371369, NM_001371370, NM_001371371, NM_001371372, NM_001371373, NM_001371374, NM_001371376, NM_020152

CCDS: CCDS13584, CCDS68182, CCDS74775

Canonical transcript exons

ENST00000399928 — 5 exons

Exon	Start	End
ENSE00001540840	29130644	29130923
ENSE00003577947	29133306	29133414
ENSE00003896872	29174712	29175887
ENSE00004011614	29149189	29149250
ENSE00004011615	29159941	29160056

Expression profiles

Bgee: expression breadth ubiquitous, 200 present calls, max score 99.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.2305 / max 1286.6263, expressed in 1068 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188730	6.2556	701
188724	0.8013	310
188725	0.5740	232
188726	0.5070	158
188721	0.3093	158
188727	0.2661	87
188731	0.1748	36
188729	0.1700	53
188728	0.1255	51
188722	0.0360	19

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	99.20	gold quality
mononuclear cell	CL:0000842	98.90	gold quality
leukocyte	CL:0000738	98.52	gold quality
oocyte	CL:0000023	94.90	gold quality
right coronary artery	UBERON:0001625	93.14	gold quality
saphenous vein	UBERON:0007318	91.13	gold quality
granulocyte	CL:0000094	90.66	gold quality
secondary oocyte	CL:0000655	90.49	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.20	gold quality
tibial artery	UBERON:0007610	88.78	gold quality
popliteal artery	UBERON:0002250	88.76	gold quality
blood vessel layer	UBERON:0004797	88.74	gold quality
aorta	UBERON:0000947	88.26	gold quality
artery	UBERON:0001637	88.24	gold quality
ascending aorta	UBERON:0001496	88.02	gold quality
gastrocnemius	UBERON:0001388	88.01	gold quality
muscle of leg	UBERON:0001383	87.89	gold quality
thoracic aorta	UBERON:0001515	87.83	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.52	silver quality
blood	UBERON:0000178	87.49	gold quality
left coronary artery	UBERON:0001626	86.63	gold quality
coronary artery	UBERON:0001621	85.92	gold quality
skeletal muscle organ	UBERON:0014892	85.82	gold quality
muscle organ	UBERON:0001630	85.80	gold quality
descending thoracic aorta	UBERON:0002345	85.43	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.63	gold quality
gall bladder	UBERON:0002110	82.07	gold quality
body of tongue	UBERON:0011876	81.96	silver quality
vastus lateralis	UBERON:0001379	81.47	silver quality
bone marrow cell	CL:0002092	81.06	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-11	yes	22.54
E-GEOD-99795	no	15.87
E-ANND-3	no	5.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

47 targeting MAP3K7CL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-579-3P	99.86	71.66	3628
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3660	99.68	67.33	1149
HSA-MIR-4526	99.68	67.07	1136
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-3923	99.52	69.21	446
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-4717-3P	99.06	66.34	1072
HSA-MIR-4716-5P	98.82	68.57	1168
HSA-MIR-4646-3P	98.65	66.98	693
HSA-MIR-3192-3P	98.62	65.80	970

Literature-anchored findings (GeneRIF, showing 1)

• Genome-wide identification of lncRNAs and mRNAs differentially expressed in human vascular smooth muscle cells stimulated by high phosphorus. (PMID:32401115)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
rattus_norvegicus	Map3k7cl	ENSRNOG00000001584

Paralogs (2): MAP3K7 (ENSG00000135341), PKDCC (ENSG00000162878)

Protein

Protein identifiers

MAP3K7 C-terminal-like protein — P57077 (reviewed: P57077)

Alternative names: TAK1-like protein

All UniProt accessions (6): P57077, B0EVZ6, B0EVZ8, B4DFW0, C9J990, C9JLK6

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Detected in lung and peripheral blood leukocytes. Expressed predominantly in peripheral blood leukocytes and ubiquitously in adult and fetal tissues. Also expressed strongly in breast carcinoma GI-101, colon adenocarcinoma GI-112, and prostatic adenocarcinoma PC3.

Domain organisation. Contains a C-terminal domain similar to that of the C-terminal section of MAP3K7.

Isoforms (2)

UniProt ID	Names	Canonical?
P57077-4	1, D	yes
P57077-1	2, A

RefSeq proteins (15): NP_001273546, NP_001273547, NP_001273548, NP_001273549, NP_001273551, NP_001273552, NP_001273563, NP_001358298, NP_001358299, NP_001358300, NP_001358301, NP_001358302, NP_001358303, NP_001358305, NP_064537 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR042800	Map3k7cl	Family

UniProt features (6 total): sequence conflict 3, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P57077-F1	85.09	0.65

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 94 (showing top): KOYAMA_SEMA3B_TARGETS_UP, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, OSMAN_BLADDER_CANCER_DN, SENESE_HDAC1_AND_HDAC2_TARGETS_UP, chr21q21, CHICAS_RB1_TARGETS_CONFLUENT, SHARMA_ASTROCYTOMA_WITH_NF1_SYNDROM, CERIBELLI_PROMOTERS_INACTIVE_AND_BOUND_BY_NFY, PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP, KATSANOU_ELAVL1_TARGETS_UP, KRIEG_HYPOXIA_NOT_VIA_KDM3A, PEDRIOLI_MIR31_TARGETS_DN, LIM_MAMMARY_STEM_CELL_UP, PRC2_EED_DN.V1_UP, BMI1_DN_MEL18_DN.V1_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

816 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAP3K7CL	RWDD2B	P57060	471
MAP3K7CL	SLC12A9	Q9BXP2	467
MAP3K7CL	C21orf58	P58505	447
MAP3K7CL	MUSTN1	Q8IVN3	425
MAP3K7CL	SPATC1L	Q9H0A9	406
MAP3K7CL	RERGL	Q9H628	389
MAP3K7CL	ART3	Q13508	386
MAP3K7CL	EVA1C	P58658	372
MAP3K7CL	YBEY	P58557	371
MAP3K7CL	SMIM11	P58511	367
MAP3K7CL	RWDD2A	Q9UIY3	354
MAP3K7CL	MRPS6	P82932	310
MAP3K7CL	HNRNPA1L3	A0A2R8Y4L2	306
MAP3K7CL	MTRES1	Q9P0P8	297
MAP3K7CL	PCDH17	O14917	286
MAP3K7CL	PHF11	Q9UIL8	286

IntAct

5 interactions, top by confidence:

A	B	Type	Score
GPS2	MAP3K7CL	psi-mi:“MI:0915”(physical association)	0.510
MAP3K7CL	GPS2	psi-mi:“MI:0915”(physical association)	0.510
MAP3K7CL	CISH	psi-mi:“MI:0915”(physical association)	0.370
MAP3K7CL	TAB3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (15): MAP3K7CL (Two-hybrid), MAP3K7CL (Two-hybrid), AK8 (Two-hybrid), TAB3 (Two-hybrid), TAB3 (Two-hybrid), MAP3K7CL (Two-hybrid), MAP3K7CL (Affinity Capture-Western), MAP3K7CL (Two-hybrid), MAP3K7CL (Two-hybrid), TAB3 (Two-hybrid), USF1 (Two-hybrid), AK8 (Two-hybrid), MAP3K7CL (Affinity Capture-MS), MAP3K7CL (Reconstituted Complex), CISH (Two-hybrid)

ESM2 similar proteins: A0A1L8GUX5, A0A1L8GXY6, A0A1W2P884, A2AIW0, A2AM05, A2CE83, A6H5Y1, E7F5E1, F7DP49, H2MTR9, O08970, O60296, P27628, P28290, P57077, Q08AD1, Q0VF96, Q28GJ0, Q2KJD6, Q2MJV9, Q3KQW7, Q3V036, Q4KLH6, Q4KM62, Q4R815, Q5R9L2, Q5SZL2, Q5TB80, Q5U2Y9, Q5U4W1, Q66H35, Q6AW69, Q6IRN6, Q6PD31, Q6ZQ06, Q70YC5, Q7ZX27, Q80ST9, Q86VQ0, Q8C115

Diamond homologs: A2VDU3, O43318, P0C8E4, P57077, P58500, Q5RFL3, Q62073

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2923 predictions. Top by Δscore:

Variant	Effect	Δscore
21:29085913:TTAAG:T	donor_loss	1.0000
21:29085914:TAAGG:T	donor_loss	1.0000
21:29085915:AAGG:A	donor_loss	1.0000
21:29085918:GTAT:G	donor_loss	1.0000
21:29085919:T:A	donor_loss	1.0000
21:29089809:G:GT	donor_gain	1.0000
21:29159936:T:TA	acceptor_gain	1.0000
21:29159939:A:AG	acceptor_gain	1.0000
21:29159940:G:GG	acceptor_gain	1.0000
21:29160052:AGGAA:A	donor_gain	1.0000
21:29160053:GGAA:G	donor_gain	1.0000
21:29160053:GGAAG:G	donor_gain	1.0000
21:29160054:GAA:G	donor_gain	1.0000
21:29160054:GAAG:G	donor_gain	1.0000
21:29160055:AAGTA:A	donor_loss	1.0000
21:29160056:AGTA:A	donor_loss	1.0000
21:29160057:G:GG	donor_gain	1.0000
21:29160058:TAAG:T	donor_loss	1.0000
21:29084758:GGAGG:G	donor_gain	0.9900
21:29084759:GAGGG:G	donor_gain	0.9900
21:29084760:A:T	donor_gain	0.9900
21:29085807:CCCCA:C	acceptor_loss	0.9900
21:29085808:CCCA:C	acceptor_loss	0.9900
21:29085809:CCAGG:C	acceptor_loss	0.9900
21:29085810:CA:C	acceptor_loss	0.9900
21:29085811:A:T	acceptor_loss	0.9900
21:29089797:G:GT	donor_gain	0.9900
21:29089801:G:GT	donor_gain	0.9900
21:29089805:G:GT	donor_gain	0.9900
21:29091666:A:AG	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000004672 (21:29081698 C>A), RS1000024976 (21:29124973 C>T), RS1000099207 (21:29138112 G>T), RS1000108321 (21:29096514 A>T), RS1000118299 (21:29096109 T>A), RS1000122447 (21:29093623 CG>C), RS1000129571 (21:29084081 A>T), RS1000160635 (21:29083797 T>C), RS1000201254 (21:29090357 A>C,G), RS1000229654 (21:29131697 C>T), RS1000240980 (21:29131390 T>G), RS1000269456 (21:29174399 A>G), RS1000298845 (21:29089785 A>C), RS1000343985 (21:29137217 A>G), RS1000380773 (21:29154694 C>T)

Disease associations

OMIM: gene MIM:611110 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

35 associations (top):

Study	Trait	p-value
GCST001786_3	Dental caries	5.000000e-06
GCST002157_1	Response to mTOR inhibitor (everolimus)	8.000000e-06
GCST005194_138	Coronary artery disease	5.000000e-09
GCST005195_60	Coronary artery disease	4.000000e-09
GCST005196_248	Coronary artery disease	2.000000e-09
GCST005937_1	Ventricular ectopy	2.000000e-06
GCST006019_40	Gamma glutamyl transferase levels	1.000000e-10
GCST007645_6	Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)	8.000000e-07
GCST010796_256	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-09
GCST010796_257	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_258	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_4752	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-48
GCST010796_4753	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_4754	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-11
GCST010796_4755	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-14
GCST010796_4756	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-17
GCST010796_4757	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-19
GCST010796_4758	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-21
GCST010796_4759	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-22
GCST010796_4760	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-25
GCST010796_4761	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-28
GCST010796_4762	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-31
GCST010796_4763	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-33
GCST010796_4764	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-31
GCST010796_4765	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-32
GCST010796_4766	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-33
GCST010796_4767	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-37
GCST010796_4768	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-39
GCST010796_4769	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-45
GCST010796_4770	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-31

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005417	response to mTOR inhibitor
EFO:0009276	ventricular ectopy
EFO:0004532	serum gamma-glutamyl transferase measurement
EFO:0005199	renal transplant outcome measurement
EFO:0004327	electrocardiography

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects cotreatment, increases abundance	3
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	2
Acrolein	affects cotreatment, decreases expression, increases abundance	2
Air Pollutants	affects cotreatment, decreases expression, increases abundance	2
Ozone	affects cotreatment, decreases expression, increases abundance	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, decreases methylation	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	increases expression	1
aflatoxin B2	increases methylation	1
nickel sulfate	increases expression	1
diallyl trisulfide	increases expression	1
chromium hexavalent ion	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation, affects methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.